Sanofi shares rise 1.56% intraday after strategic investment in Adagene and Phase 1b/2 trial initiation.

Sanofi rose 1.56% intraday, with the company's strategic investment in Adagene and the initiation of a Phase 1b/2 trial in combination with ADG126 in over 100 patients. Additionally, the approval of Keytruda for PD-L1+ head & neck cancer as neoadjuvant and adjuvant therapy by Health Canada, based on the Phase 3 KEYNOTE-689 trial, further bolstered investor confidence.